# A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

> **NCT07445906** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Renal Impairments
- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** RG002C0106

## Key facts

- **NCT ID:** NCT07445906
- **Lead sponsor:** Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07445906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07445906, "A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07445906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*